Can Tumor Mutational Burden Guide Treatment in Metastatic Breast Cancer?
A study presented at the San Antonio Breast Cancer Symposium examined whether tumor mutational burden (TMB) was associated with outcomes in hormone receptor-positive, HER2-negative metastatic breast cancer patients treated with either pembrolizumab (Keytruda) or chemotherapy. Findings showed that patients with high TMB had numerically more favorable survival when treated with the immune checkpoint inhibitor. In …
Can Tumor Mutational Burden Guide Treatment in Metastatic Breast Cancer? Read More »